Mars 2017


Symetis and Boston Scientific reach USD 435 million purchase agreement
Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease. Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions. Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.